Show simple item record

dc.contributor.authorWandeler, Gilles
dc.contributor.authorKeiser, Olivia
dc.contributor.authorMulenga, Lloyd
dc.contributor.authorHoffmann, Christopher J
dc.contributor.authorWood, Robin
dc.contributor.authorChaweza, Thom
dc.contributor.authorBrennan, Alana
dc.contributor.authorProzesky, Hans
dc.contributor.authorGarone, Daniela
dc.contributor.authorGiddy, Janet
dc.contributor.authorChimbetete, Cleophas
dc.contributor.authorBoulle, Andrew
dc.contributor.authorEgger, Matthias
dc.date.accessioned2012-12-11T20:40:46Z
dc.date.available2012-12-11T20:40:46Z
dc.date.issued2012-09-01
dc.identifier.citationTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. 2012, 61 (1):41-8 J. Acquir. Immune Defic. Syndr.en_GB
dc.identifier.issn1944-7884
dc.identifier.pmid22743595
dc.identifier.doi10.1097/QAI.0b013e3182632540
dc.identifier.urihttp://hdl.handle.net/10144/255348
dc.descriptionArticle approval pending
dc.description.abstractTenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/22743595en_GB
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en_GB
dc.subjectHIV/AIDSen_GB
dc.subject.meshAdenineen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAfrica South of the Saharaen_GB
dc.subject.meshAnti-Retroviral Agentsen_GB
dc.subject.meshAntiretroviral Therapy, Highly Activeen_GB
dc.subject.meshCD4 Lymphocyte Counten_GB
dc.subject.meshCohort Studiesen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPhosphonic Acidsen_GB
dc.subject.meshSouth Africaen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshViral Loaden_GB
dc.subject.meshZambiaen_GB
dc.titleTenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.en
dc.typeArticleen
dc.contributor.departmentDivision of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. gwandeler@ispm.unibe.chen_GB
dc.identifier.journalJournal of acquired immune deficiency syndromes (1999)en_GB
refterms.dateFOA2019-03-04T10:05:59Z
html.description.abstractTenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).


Files in this item

Thumbnail
Name:
Wandeler tenofovir in second-line ...
Size:
452.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record